VioxxA selective Cox-2 inhibitorthat has anti-inflammatory properties

Vioxx (CAS 162011-90-7)

Vioxx | CAS 162011-90-7 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_23, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_208486, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 78ms
  • REVIEWS, PRODUCT
Synonym: Rofecoxib; 4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
Application: A selective Cox-2 inhibitorthat has anti-inflammatory properties
CAS Number: 162011-90-7
Molecular Weight: 314.36
Molecular Formula: C17H14O4S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits
Appearance :
Crystalline powder
Physical State :
Solid
Solubility :
Soluble in water (<1 mg/ml at 25° C), DMSO (63 mg/ml at 25° C), methanol (slightly), DMF, and ethanol (<1 mg/ml at 25° C).
Storage :
Store at 4° C
Melting Point :
211° C
Boiling Point :
577.6° C at 760 mmHg
Density :
1.33 g/cm3
Refractive Index :
n20D 1.62
IC50 :
Cyclooxygenase-2: IC50 = 0.19 nM (mouse); COX-2: IC50 = 1 nM (human); Lipopolysaccharide-induced, COX-2-derived PGE2 synthesis: IC50 = 0.53 µM; COX-1-derived thromboxane B2 synthesis after blood coagulation: IC50 = 18.8 µM; Phenacetin O-deethylation: IC50 = 23 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
LU5135000
PubChem CID :
5090
MDL Number :
MFCD00935806
Beilstein Registry :
8269007
SMILES :
CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Vioxx  Product Citations

See how others have used Vioxx. Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 23652407  Tamraz, B. et al. 2013. Pharmacogenet. Genomics. 23: 355-64.

PMID: # 22419147  Floyd, JS. et al. 2012. Clin. Pharmacol. Ther. 91: 896-904.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 69ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Fujishita Fujishita, T. et al. (PubMed 25855137) found that inhibition of stromal Cox-2 via Vioxx effected antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc( 716) mice. -SCBT Publication Review
Date published: 2015-03-19
  • y_2019, m_9, d_23, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_208486, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.